In a first-of-its-kind study, tofacitinib significantly reduced disease activity and glucocorticoid steroid use in patients with polymyalgia rheumatica (PMR).

Glucocorticoids are the mainstay for the treatment of polymyalgia rheumatica (PMR). Tofacitinib is a JAK inhibitor that has shown efficacy in reducing inflammation and disease activity in PMR by suppressing the...